cost-effectiveness analysis of biogeneric recombinant activated factor vii (aryoseven™) and activated prothrombin complex concentrates (feiba™) to treat hemophilia a patients with inhibitors in iran

Authors

mina golestani school of pharmacy, shahid beheshti university of medical sciences, tehran, iran, iranian center of excellence in health management, faculty of management and medical informatics, tabriz university of medical sciences, tabriz, iran

peyman eshghi pediatric hematology and oncology , pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran

hamid reza rasekh school of pharmacy, shahid beheshti university of medical sciences, tehran, iran

abdoll majid cheraghali school of pharmacy, university of baqiyatallah medical sciences, tehran, iran

abstract

abstract nowadays, bypassing agents such as recombinant activated factor vii (rfviia) and activated prothrombin complex concentrates (apcc) are used to treat bleeding episodes in the hemophilia patients with inhibitors. aryoseven® is an iranian biogeneric rfviia with homogeneity of efficacy and the nature to novoseven in a comparative trial. the current clinical trial aimed to evaluate the cost-effectiveness of feiba and aryoseven® by decision analytic model according to the iranian healthcare system. an open label, multi-center, cross-over clinical trial was designed. patients were categorized into 3 groups based on their prior tendency to one or none of the products. to determine the premium therapeutic strategy, the incremental cost-effectiveness ratio (icer) was calculated. protocol f led to more treatment success in group f than the other groups (p= 0.03). also, there was a significant statistical difference between the mean of effectiveness scores in the groups using protocol f (p = 0.01). the effectiveness of protocol f and a were 89% and 72%, respectively. icer cost us$ 5,146 to manage an episode of bleeding to get one more unit of effectiveness using feiba vs. aryoseven. although the results showed that aryoseven was more cost-effective compared to feiba, the two strategies were undominated. in other words, both medicines can be applied in the first line of the treatment if the cost of feiba was reduced. the present clinical trial was registered at irct website, under id no.2013020612380n1.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

full text

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

full text

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost-effectiv...

full text

Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience

BACKGROUND Currently, the greatest challenge in hemophilia treatment is managing hemophilia patients with inhibitors. The two main bypassing agents that are used to treat hemophilia patients with inhibitors are activated prothrombin complex concentrates (APCC) and recombinant factor VIIa (rFVIIa). Hemophilia patients with inhibitors can develop bleeding episodes, that are refractory to monother...

full text

Cost Minimization Analysis of Activated Prothrombin Complex Concentrate (Apcc) Compared To Recombinant Factor Viia (Rfviia) for Hemophilia Patients With Inhibitors.

REFERENCES [1] Bonnet, P., et al. „Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.“ Haemophilia (2009): 1-7. [2] Astermark, J., et al. „A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Compar...

full text

Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.

BACKGROUND Recombinant activated factor VII (rFVIIa) is indicated in bleeding patients when a life-threatening haemorrhage occurs. Prothrombin complex concentrates (PCCs) are also used for this indication in several countries, without any evidence-based rationale. Our objective was to compare the efficacy and safety of PCC and rFVIIa in a model of bleeding and thrombosis in haemodiluted rabbits...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of pharmaceutical research

جلد ۱۵، شماره ۲، صفحات ۶۶۹-۶۷۷

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023